Clinical Trial Feasibility Assessment: The Complete Site Guide

Most research sites complete a feasibility questionnaire, submit it, and wait for the sponsor to decide. That is the passive version of feasibility. The sites that win the best studies and consistently outperform on enrollment treat feasibility as a two-directional evaluation: they assess the study as rigorously as the sponsor assesses them. This guide covers how to do that, from the six domains of internal readiness to the go/no-go decision framework that separates sites with strong sponsor relationships from sites that keep missing their targets.

What a Feasibility Assessment Actually Is (From the Site's Side)

A clinical trial feasibility assessment is formally defined as the process by which a sponsor or CRO evaluates whether a given site can successfully conduct a specific study. That definition is accurate, but incomplete.

Feasibility is a two-directional process. The sponsor evaluates your site. You evaluate the study. Most sites do the first part thoroughly and skip the second entirely.

The result: sites commit to studies they cannot execute, enrollment falls short, sponsor relationships take damage, and the coordinators managing the gap burn out. None of that is inevitable. It starts with treating the sponsor's feasibility questionnaire as the floor, not the ceiling, of your evaluation.

Your internal feasibility assessment asks a different set of questions. Do you have the right patient population? Can you realistically hit the enrollment target the sponsor expects? Does this study fit your current portfolio without cannibalizing enrollment in your active trials? Does your team have the bandwidth and the specific procedural capabilities this protocol requires?

Answering those questions accurately is what separates sites that get re-selected from sites that get replaced. For a step-by-step walkthrough of the feasibility process itself, see our guide to running a feasibility assessment.

The Cost of a Bad Yes

When a site overestimates its feasibility and commits to a study it cannot deliver, the downstream effects compound quickly.

Enrollment misses are the most visible consequence, but they are not the most damaging one. Sponsors track site performance at the portfolio level. A site that misses its enrollment target once is noted. A site that misses repeatedly gets deprioritized for future studies, which carries a significant business consequence for sites whose revenue depends on study volume.

The less visible costs are internal. Coordinators assigned to a struggling study absorb the weight of unmet targets. They run additional pre-screening calls, field sponsor escalations, and manage visit schedules that cannot fill. That workload does not disappear when the study ends. It compounds the enrollment challenges that follow a bad commitment across every active trial they are managing simultaneously.

There is also a financial dimension. Sites that accept milestone-based payments and miss enrollment milestones delay their own revenue. For smaller sites running lean operations, that cash flow gap matters.

A confident no to the wrong study is worth more to a site's long-term sponsor relationships than a struggling yes.

The Six Domains of Site Readiness

Before any study decision, a site should evaluate its readiness across six domains. This framework, established in peer-reviewed clinical research literature (PMC, 2023), organizes the internal variables a site must honestly assess before committing. Each domain contains a set of questions a site director or PI should answer before the clinical trial agreement is signed.

Honest self-assessment across all six domains takes two to four hours per study. That investment prevents the downstream costs of a commitment made without full information.

How to Read a Protocol for Feasibility Signals

The protocol is the most information-dense document in a feasibility evaluation. Most sites read it for inclusion and exclusion criteria and stop there. Four elements of a protocol determine your site's ability to perform, and each deserves a deliberate read.

The enrollment target is one number in the protocol. The numbers that determine whether you can hit it are in the visit schedule, the eligibility criteria, and the procedural requirements.

Patient Population Match: Your Most Critical Feasibility Variable

Patient population is where sites most consistently overestimate their feasibility. A coordinator reviews inclusion criteria, recalls three or four patients who might qualify, and projects that intuition into an enrollment commitment of 15. The math does not hold.

A realistic patient population estimate starts with your existing patient database, not your intuition. Pull the patients in your EHR who match the broad indication. Then apply the specific eligibility criteria one at a time. At each filter, a portion of your initial pool drops out. The number remaining after all criteria are applied is your realistic ceiling, before accounting for dropout, consent failure, and competing trial exclusions.

Your referral channel capacity matters as much as your internal database. If your site relies on community physician referrals for enrollment, map those channels explicitly. How many referring physicians are active? What is the average referral volume per month? Does this protocol's indication align with what those physicians are currently seeing in their practices?

Check ClinicalTrials.gov for competing studies enrolling the same patient population in your geography. A patient who qualifies for your study also qualifies for the competing study across town. Within-geography enrollment competition is a real and quantifiable drain on feasibility that most internal estimates do not account for.

Your enrollment commitment should be built from a documented patient estimate, not from experience with similar-sounding protocols.

Use our free feasibility assessment tool to generate a data-backed enrollment feasibility report for a specific NCT ID and your site's geography before your internal decision meeting.

Portfolio Fit and Competing Trial Overlap

This dimension is almost entirely absent from published feasibility guides. It deserves its own evaluation.

Every study you agree to run competes for the same patient pool and coordinator bandwidth as the studies you are already running. Two trials enrolling moderate-to-severe psoriasis patients at the same site draw from the same pool. When your lead coordinator is managing four active studies, adding a fifth does not distribute workload evenly. In practice, it often degrades performance across all five.

Before accepting a new study, run three checks against your current portfolio.

Portfolio fit is not a soft consideration. It is a quantifiable variable that determines whether your enrollment commitment on the new study is real or theoretical.

Making the Go/No-Go Decision

A feasibility evaluation that covers all six readiness domains, the four protocol signals, patient population match, and portfolio fit produces enough information to make a structured decision.

Use our free feasibility assessment tool to generate a site-level report for your specific NCT ID and geography before your internal decision meeting. It gives you a structured output you can use to anchor the conversation with your team and the sponsor.

The goal of a feasibility evaluation is not to find reasons to say yes. It is to find the studies where a yes is a commitment you can keep.

How Feasibility Performance Builds Preferred-Site Status

Sponsors and CROs track feasibility accuracy at the site level over time. A site that consistently submits realistic estimates and then performs at or above them earns a category of trust that is difficult for competitors to replicate: preferred-site status.

Preferred sites get invited into feasibility assessments earlier, before studies reach broad distribution. They receive more favorable budget negotiations. They are the first call when a sponsor needs to add a site to a study that is falling behind. That pipeline of early access and favorable terms is the business development asset that a strong feasibility track record builds over time.

The inverse is equally documented. Sites that habitually overestimate their feasibility receive fewer invitations. Sponsors have long institutional memories, and enrollment performance history follows a site through every future proposal.

Clinical Enroll works with research sites across 30+ indications to accelerate enrollment on studies that are already underway. Our published results include 60+ randomized patients across pharmaceutical sponsors including AstraZeneca, Sanofi, GSK, vTv Therapeutics, and Blue Lake Biotechnology, with an average cost per randomized patient of $1,167 across our six published case studies.

Sites that manage feasibility well enroll faster and build the sponsor relationships that generate the next opportunity. If your site is managing a study where enrollment has fallen behind, check if your study qualifies for a Clinical Enroll patient recruitment campaign.